PeproMene Bio Reports Complete Remission in First Follicular Lymphoma Patient from Phase 1 Trial

PeproMene Bio, Inc. (PMB), a clinical-stage biotechnology firm focused on developing innovative treatments for cancer and immune-related conditions, announced that the first follicular lymphoma (FL) patient enrolled in its Phase 1 PMB-102 study has reached complete remission just one month after receiving therapy.

The ongoing PMB-102 trial is evaluating PMB-CT01, a BAFFR-targeted CAR T cell therapy, in patients with relapsed or refractory (r/r) B-cell non-Hodgkin’s lymphoma (B-NHL). The company confirmed that this latest result brings the total number of patients achieving complete remission (CR) in the study to seven, all of whom have shown durable responses with a safety profile described as manageable.

"We are excited to report that a patient with r/r FL has achieved complete remission after treatment with PMB-CT01, bringing the total to seven patients—all achieving a 100% CR rate with durable responses and a manageable safety profile. Notably, this patient had previously undergone 7 prior lines of therapy including chemoimmunotherapies, CD19 CAR T cells, an investigational trispecific antibody, and an antibody-drug conjugate (ADC).

Remarkably, the patient experienced no CRS or ICANS," said Elizabeth Budde M.D., Ph.D., lead principal investigator for the study and associate professor of hematology at City of Hope, one of the country’s leading cancer research and treatment centers.

Follicular lymphoma is recognized as the most prevalent slow-progressing type of B-cell non-Hodgkin lymphoma, accounting for roughly 20% of NHL cases in the United States. Although current therapies can help manage the disease, FL remains incurable, and relapse is common. With each recurrence, remission tends to become shorter, and the need for new treatment strategies becomes more urgent.

"IFLI is dedicated to accelerating the development of innovative treatment options for patients with r/r FL," said Dr. Michel Azoulay, M.D., Chief Medical Officer at the Institute for Follicular Lymphoma Innovation. "I am very excited that PMB-CT01 has shown promising efficacy and safety in this first FL patient."

Hazel Cheng, Ph.D., Chief Operating Officer at PeproMene Bio, added: "Most of the PMB-102 trial participants relapsed after CD19 CAR T therapy and/or presented with CD19 negative tumors. PMB-CT01 could present a viable alternative option for patients facing this challenging scenario. We are deeply committed to the development of this first-in-class BAFFR CAR T therapy and are excited to advance our study into a multi-site expansion phase that will include r/r MCL, DLBCL and FL patients."